Clinical Trials for PLX3397 (oral)

2 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCPHI1328
09/05/2013
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination with Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma
TreatmentVICCPHI0958
02/05/2010
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.